Akebia Therapeutics, Inc.
AKBAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Akebia Therapeutics, Inc. (AKBA) is listed under Drug Manufacturers - Specialty & Generic. At a $359.5M market cap, Akebia Therapeutics, Inc. ranks as a small-cap company within healthcare. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Market Cap
$359.5M
Beta
0.23
P/E (TTM)
—
P/E (Fwd)
-7.05
EPS (TTM)
$-0.08
EPS (Fwd)
$-0.19
ROE
-79.0%
ROA
2.0%
Cash
$162.6M
Total Debt
$197.5M
Free CF
$65.8M
52W Change
-65.3%
Annual Financials
Cash vs Debt
On the balance sheet, AKBA has $162.6M in cash with $197.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $65.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -79.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $292.5M (2022) to $236.2M (2025), a 19% decline worth watching.
AKBA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AKBA.